TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of participants with 4-fold or greater rises in HMPV neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in wall motion score index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants reaching target control of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants reaching target blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants reaching target cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-year recurrence-free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Urine Assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with negative sputum cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Spinal Cord Gray Matter Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the number of apnea/hypopnea episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Zinc/PSA Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: pass/fail rate for the Brigance Preschool Screen II
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lymphatic anatomy description
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total IgG against EBOV-GP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscle force decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in balance and gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in memory and cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall Clinical Benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intent to Donate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Number of Calories Purchased From Sugar-sweetened Beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of fever
Endpoint domain: Adverse events/effects
Primary endpoint: Optical nerve sheath diameter changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Procedural feasibility through successful completion of implant and therapy adjustment procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: SAE Rates
Endpoint domain: Adverse events/effects
Primary endpoint: Change in acute insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average cost of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Average Cost of medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall treatment cost of acute appendicitis patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Sexual Function (Total FSFI Scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attendance at Primary Care Appointment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Blood measures of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of digestive acquisition of any type of RI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of laboratory-confirmed hospital-onset CDI cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PTSD Coach app Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood flow to the nucleus accumbens and connected striatal regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of successfully enrolled patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined adherence endpoint
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perioperative blood loss in mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite criteria of success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline creatinine concentration at 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline alanine aminotransferase (ALT) concentration at 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Spleen Volume Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Anemia Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of acute treatment-related grade 3 or higher toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Ipsilateral breast tumor recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of late treatment-related grade 3 or higher toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Attentional Bias Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risky Decision Making Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Fluid Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Estrogen levels in nipple aspirate fluid (NAF) and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Formation of urinary 2-, 16α-, and 4-hydroxy estrogen metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to the first opioid analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of 18F-FDG PET/MRI in differentiating pancreatic cystic neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathological Complete Tumor Regression (TRG1a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sub-total Tumor Regression (TRG1b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in High Molecular Weight Adiponectin (HMW-A) Concentration in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With PCR-Corrected ACPR on Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS symptom grade score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with improved NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of patients with improved insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Maintaining Previous Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Stricture Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: pharmacokinetics (pK) of ASA404
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CPR Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abiraterone Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion Responding to Treatment Based Upon a PSA Decline of > 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Limiting Toxicities for Each Dose Level
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients with Complete Remission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients with Progressive Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients with Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Subjects That Experience a Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Endogenous Glucose Production (EGP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of muscle hypertonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in the concentration of faecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the concentration of inflammatory markers in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in faecal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale Mean Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Social Behavior Impairment (SBI) Composite
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change From Baseline in Social Cognition (SC) Composite
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Binocular uncorrected distance, intermediate, and near visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular uncorrected depth of focus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Survey SF-12v2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (Cantril Ladder)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Globe Akinesia Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with an Acute Coronary Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Avoidance of unprotected sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Use of birth control
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Presence of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Accumulative excretion rate of SHR3824 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shear Wave Velocity Measurements in the Abdominal Wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accelerated Acquisition Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parental Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Were Alive 1 Year After Start of Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Presence of a tumor of the small intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Malnutrition Inflammation Score (MIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peripheral Neuropathy Total Symptom Score (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Steady-state plasma itraconazole concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Reporting Moderately or Markedly Improved Responses on the GRA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Toleration of Solid Food
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite of fatal and non-fatal cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Achievement of target blood pressure (< 140 mmHg/90 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sleepiness in the morning
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Efficacy of PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLT occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rate after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Effective PDA Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of LVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial NO production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VCAM-1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ROS generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sound quality ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite obstetrical/perinatal endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Received Pre-test Genetic Counseling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of DNR-orders
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Dose-limiting toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Analgesic use post-operatively (during hospital stay)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Analgesic use post-discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Live birth rate per participant
Endpoint domain: Mortality/survival
Primary endpoint: Change in neurocognitive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraoperative Hemostasis at Target Bleeding Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Glucose, insulin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of plasma protein F content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean growth over 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in head circumference over 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of stereotypic movements at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In hospital mortality up to 30 days after admission
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change Assessed by FACBC PET Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Specific Antigen Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Responding to Treatment Assessed by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Responding to Treatment Assessed by CT Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Clinical Response Assessed by Bone Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: molecular-subtype heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in family health, happiness and harmony
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: bacterial infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: high-risk behavior
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Falls incidence change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Local Skin Responses (LSR)
Endpoint domain: Adverse events/effects
Primary endpoint: Non-esterified fatty acids (NEFA) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients screened and allocated to trials
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30-day New-Onset Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in vent flow of the mask system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Without Exacerbations of the Underlying Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic Use
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of days spent at home by the AD patient
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Correct pregnancy test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: safety of EBV-specific CTL
Endpoint domain: Adverse events/effects
Primary endpoint: anti-tumor effects of EBV-specific CTL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of Inspiratory capacity (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 30 Second Chair Standing Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 40m Fast Paced Walking Test (40m FPWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Stair Climb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Lorazepam Dose Over the First 12 Hours of Alcohol Withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Lorazepam Dose Over the First 24 Hours of Alcohol Withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Lorazepam Dose Over the 72 Hours of Alcohol Withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET Scan AB Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of symptom-free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Patients Who Agree to Change in Their Opioid Regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bioeffect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in surgical anesthesia effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in global score on the Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Measure of ratio Ku70/XRCC6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-HAV seropositivity status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of courses of G-CSF required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention